| In intervention schools | In broader community | ||
---|---|---|---|---|
 | All students | Sexually active students | All people | Sexually active people |
Philadelphia | ||||
 Prevalence in baseline scenario (%) | 3.10 (2.78–3.44) | 5.03 (4.39–5.42) | 3.10 (2.78–3.44) | 5.03 (4.39–5.42) |
 Reduction in prevalence with screeningb | ||||
  At 30% coverage, with stable participation | 0.85 (0.74–0.95) | 1.38 (1.22–1.49) | 0.28 (0.24–0.32) | 0.45 (0.39–0.50) |
  At 30% coverage, with declining participation | 0.15 (0.12–0.17) | 0.24 (0.20–0.27) | 0.05 (0.04–0.07) | 0.08 (0.07–0.10) |
  At 30% coverage, with increasing participation | 1.28 (1.12–1.42) | 2.09 (1.84–2.23) | 0.42 (0.36–0.48) | 0.68 (0.59–0.75) |
  At 20% coverage, with stable participation | 0.84 (0.73–0.94) | 1.37 (1.21–1.48) | 0.19 (0.16–0.21) | 0.30 (0.26–0.34) |
  At 40% coverage, with stable participation | 0.86 (0.75–0.96) | 1.40 (1.23–1.50) | 0.37 (0.32–0.43) | 0.60 (0.52–0.67) |
  At 60% coverage, with stable participation | 0.87 (0.76–0.98) | 1.42 (1.25–1.53) | 0.55 (0.48–0.63) | 0.89 (0.78–0.99) |
Chicago | ||||
 Prevalence in baseline scenario (%) | 4.12 (2.07–5.48) | 7.01 (3.09–9.28) | 4.12 (2.07–5.48) | 7.01 (3.09–9.28) |
 Reduction in prevalence with screeningb | ||||
  At 30% coverage, with stable participation | 1.26 (0.62–1.76) | 2.15 (0.93–2.85) | 0.53 (0.22–0.82) | 0.91 (0.33–1.31) |
  At 30% coverage, with declining participation | 0.26 (0.12–0.42) | 0.47 (0.19–0.68) | 0.14 (0.05–0.26) | 0.23 (0.08–0.42) |
  At 30% coverage, with increasing participation | 1.85 (0.92–2.54) | 3.17 (1.36–4.17) | 0.77 (0.32–1.16) | 1.31 (0.48–1.87) |
  At 20% coverage, with stable participation | 1.21 (0.61–1.65) | 2.05 (0.91–2.73) | 0.36 (0.15–0.55) | 0.61 (0.22–0.89) |
  At 40% coverage, with stable participation | 1.31 (0.63–1.86) | 2.24 (0.94–3.02) | 0.70 (0.29–1.08) | 1.20 (0.44–1.73) |
  At 60% coverage, with stable participation | 1.44 (0.65–2.07) | 2.42 (0.97–3.39) | 1.04 (0.43–1.58) | 1.76 (0.64–2.54) |
Rural Iowac | ||||
 Prevalence in baseline scenario (%) | 0.58 (0.41–0.7) | 1.28 (0.92–1.54) | 0.58 (0.92–0.72) | 1.28 (0.92–1.54) |
 Reduction in prevalence with screeningb | ||||
  At 30% coverage, with stable participation | 0.18 (0.13–0.22) | 0.40 (0.29–0.47) | 0.07 (0.05–0.09) | 0.16 (0.12–0.19) |
  At 30% coverage, with declining participation | 0.04 (0.03–0.05) | 0.09 (0.07–0.11) | 0.02 (0.02–0.03) | 0.05 (0.04–0.06) |
  At 30% coverage, with increasing participation | 0.26 (0.18–0.32) | 0.58 (0.42–0.69) | 0.10 (0.08–0.12) | 0.23 (0.17–0.27) |
  At 20% coverage, with stable participation | 0.17 (0.12–0.21) | 0.38 (0.28–0.46) | 0.05 (0.04–0.06) | 0.11 (0.08–0.13) |
  At 40% coverage, with stable participation | 0.19 (0.13–0.23) | 0.41 (0.30–0.48) | 0.10 (0.07–0.11) | 0.21 (0.15–0.25) |
  At 60% coverage, with stable participation | 0.20 (0.14–0.24) | 0.44 (0.32–0.51) | 0.14 (0.10–0.17) | 0.31 (0.23–0.36) |